|
| 35960902 | A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. | J Clin Oncol | 2023 |
| 37537253 | A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. | Br J Cancer | 2023 |
| 37258363 | Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection. | Eur Urol | 2023 |
| 36862387 | First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. | JAMA Oncol | 2023 |
| 34491610 | Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. | BJU Int | 2022 |
| 35577644 | Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. | Eur Urol | 2022 |
| 35421369 | Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. | Lancet Oncol | 2022 |
| 35388003 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. | Nat Commun | 2022 |
| 35908256 | TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer. | BJU Int | 2022 |
| 35142815 | Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2022 |
| 33012577 | Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin. | Eur Urol | 2021 |
| 33824031 | A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33539743 | Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. | Lancet Oncol | 2021 |
| 33558714 | Urological cancer patients receiving treatment during COVID-19: a single-centre perspective. | Br J Cancer | 2021 |
| 33581875 | Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. | Eur Urol | 2021 |
| 34926759 | Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. | Gynecol Oncol Rep | 2021 |
| 34420403 | Novel Approach to Endoscopic Foreign Body Retrieval From the Gastric Body. | J Investig Med High Impact Case Rep | 2021 |
| 34006497 | Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. | Clin Genitourin Cancer | 2021 |
| 34171206 | Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. | Expert Opin Investig Drugs | 2021 |
| 33472913 | Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). | Clin Cancer Res | 2021 |
| 33293079 | Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. | Eur Urol | 2021 |
| 32576531 | The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. | Eur Urol Focus | 2021 |
| 31411990 | Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. | Eur Urol Oncol | 2020 |
| 31843338 | Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. | Eur Urol | 2020 |
| 31753727 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2020 |
| 31941968 | CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. | Sci Rep | 2020 |
| 33085669 | Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. | PLoS One | 2020 |
| 33179000 | The curious case of an atypical headache, a case report and review of literature. | AME Case Rep | 2020 |
| 32821347 | Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. | Oncotarget | 2020 |
| 32755479 | Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. | JCO Glob Oncol | 2020 |
| 32306987 | ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. | Trials | 2020 |
| 32497637 | Analysis of Gastrointestinal and Hepatic Manifestations of SARS-CoV-2 Infection in 892 Patients in Queens, NY. | Clin Gastroenterol Hepatol | 2020 |
| 30502102 | Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8]. | Eur Urol | 2019 |
| 31358380 | Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer. | Eur Urol | 2019 |
| 31235192 | Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. | Eur Urol | 2019 |
| 31113841 | Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. | Clin Cancer Res | 2019 |
| 31133463 | Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. | Crit Rev Oncol Hematol | 2019 |
| 28753879 | Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. | Eur Urol Focus | 2018 |
| 30116760 | Primary Endoscopic Closure of Duodenal Perforation Secondary to Biliary Stent Migration: A Case Report and Review of the Literature. | J Investig Med High Impact Case Rep | 2018 |
| 31158093 | From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. | Eur Urol Oncol | 2018 |
| 29273410 | Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. | Eur Urol | 2018 |
| 29268948 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. | Lancet | 2018 |
| 27256016 | Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). | BJU Int | 2017 |
| 28415688 | Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. | Oncotarget | 2017 |
| 28259975 | Gene expression profiling in bladder cancer identifies potential therapeutic targets. | Int J Oncol | 2017 |
| 28402747 | Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. | J Clin Oncol | 2017 |
| 28125821 | The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). | Br J Cancer | 2017 |
| 28098864 | VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. | Int J Oncol | 2017 |
| 28916371 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. | Lancet | 2017 |
| 28923700 | Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. | Clin Genitourin Cancer | 2017 |